Altrika Ltd has been awarded a Full Manufacturer/Importer’s Licence (MIA) by the UK Medicines and Healthcare products Regulatory Agency (MHRA). This licence will enable Altrika to export its leading allogeneic skin cell product, Cryoskin®, to global markets outside the EU where there is a significant need to treat burns and other serious skin wounds.

“The Manufacturer’s Licence is recognition by the UK’s statutory regulatory body of the standards we maintain at Altrika to ensure the quality of our medicinal products,” said Altrika CEO, Graeme Purdy. “We are committed to providing the best possible treatment for clinicians and their patients to alleviate the pain, infection risk and long term problems associated with severe skin wounds. This is a tremendous demonstration of that commitment. In addition, the licence underpins our ability to ramp up sales of Cryoskin® in support of our revenue projections in 2012 and beyond.”

Cryoskin® comprises sub-confluent cultured allogeneic keratinocytes which are presented on a patented polymer dressing for easy application to skin wounds. Used alone, or in combination with other therapies, it has demonstrated tangible improvement in the speed of recovery of wounds and the subsequent quality of the regenerated skin.

Cryoskin® is currently available on a specific patient basis for treating burn injuries in the UK. More information on Cryoskin® and Altrika’s complementary autologous skin cell treatment, Myskin®, can be found at www.altrika.com.